Journal ArticleDOI
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Bruce D. Cheson,Sandra J. Horning,B Coiffier,Margaret A. Shipp,Richard I. Fisher,J Connors,T A Lister,Julie M. Vose,Antonio J. Grillo-Lopez,A Hagenbeek,F Cabanillas,D Klippensten,W Hiddemann,R A Castellino,Nancy L. Harris,James O. Armitage,W. D. Carter,Richard T. Hoppe,George P. Canellos +18 more
TLDR
Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL), and two meetings were convened among United States and international lymphoma experts to develop a uniform set of criteria for assessing response in clinical trials.Abstract:
Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL). To achieve this, two meetings were convened among United States and international lymphoma experts representing medical hematology/oncology, radiology, radiation oncology, and pathology to review currently used response definitions and to develop a uniform set of criteria for assessing response in clinical trials. The criteria that were developed include anatomic definitions of response, with normal lymph node size after treatment of 1.5 cm in the longest transverse diameter by computer-assisted tomography scan. A designation of complete response/unconfirmed was adopted to include patients with a greater than 75% reduction in tumor size after therapy but with a residual mass, to include patients-especially those with large-cell NHL-who may not have residual disease. Single-photon emission computed tomography gallium scans are encouraged as a valuable adjunct to assessment of patients with large-cell NHL, but such scans require appropriate expertise. Flow cytometric, cytogenetic, and molecular studies are not currently included in response definitions. Response rates may be the most important objective in phase II trials where the activity of a new agent is important and may provide support for approval by regulatory agencies. However, the goals of most phase III trials are to identify therapies that will prolong the progression-free survival, if not the overall survival, of the treated patients. We hope that these guidelines will serve to improve communication among investigators and comparability among clinical trials until clinically relevant laboratory and imaging studies are identified and become more widely available.read more
Citations
More filters
Journal ArticleDOI
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
Bertrand Coiffier,Eric Lepage,Josette Brière,Raoul Herbrecht,Hervé Tilly,Reda Bouabdallah,Pierre Morel,Eric Van Den Neste,Gilles Salles,Philippe Gaulard,Felix Reyes,Pierre Lederlin,Christian Gisselbrecht +12 more
TL;DR: A randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma found the rate of complete response was significantly higher in the group that received CHOP plus r ituximabs than in thegroup that receivedCHOP alone.
Journal ArticleDOI
Revised response criteria for malignant lymphoma
Bruce D. Cheson,Beate Pfistner,Malik E. Juweid,Randy D. Gascoyne,Lena Specht,Sandra J. Horning,Bertrand Coiffier,Richard I. Fisher,Anton Hagenbeek,Emanuele Zucca,Steven T. Rosen,Sigrid Stroobants,T. Andrew Lister,Richard T. Hoppe,Martin Dreyling,Kensei Tobinai,Julie M. Vose,Joseph M. Connors,Massimo Federico,Volker Diehl +19 more
TL;DR: New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Journal ArticleDOI
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson,Richard I. Fisher,Sally F. Barrington,Franco Cavalli,Lawrence H. Schwartz,Emanuele Zucca,T. Andrew Lister +6 more
TL;DR: Recommendations to modernize recommendations for evaluation, staging, and response assessment of patients with Hodgkin lymphoma and non-Hodgkin lymphomas and enhance the ability to compare outcomes of clinical trials are made.
Journal ArticleDOI
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
TL;DR: Qualitative and quantitative approaches to 18F-FDG PET response assessment have been applied and require a consistent PET methodology to allow quantitative assessments and the proposed PERCIST 1.0 criteria should serve as a starting point for use in clinical trials and in structured quantitative clinical reporting.
Journal ArticleDOI
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
Guillaume Cartron,Laurent Dacheux,Gilles Salles,Philippe Solal-Celigny,Pierre Bardos,Philippe Colombat,Hervé Watier +6 more
TL;DR: This study showed an association between the FCGR3A genotype and clinical and molecular responses to rituximab, and will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas.
References
More filters
Journal ArticleDOI
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
Bruce D. Cheson,John M. Bennett,Michael R. Grever,Neil E. Kay,Michael J. Keating,Susan O'Brien,Kanti R. Rai +6 more
TL;DR: These revisions evolved as the guidelines were used in a systematic fashion in large clinical trials and with the experience following the use of newer, more effective agents, such as fludarabine.
Journal ArticleDOI
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.
T. A. Lister,Derek Crowther,S B Sutcliffe,E Glatstein,George P. Canellos,Robert C. Young,Saul A. Rosenberg,C A Coltman,M Tubiana +8 more
TL;DR: It was concluded that the structure of the Hodgkin's disease classification be maintained and that a new category of response to therapy, unconfirmed/uncertain complete remission (CR[u]), be introduced to accommodate the difficulty of persistent radiological abnormalities of uncertain significance.
Journal ArticleDOI
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.
Bruce D. Cheson,Peter A. Cassileth,David R. Head,Charles A. Schiffer,John M. Bennett,Clara D. Bloomfield,Richard D. Brunning,Robert Peter Gale,M. R. Grever,Michael J. Keating +9 more
TL;DR: The National Cancer Institute sponsored a workshop to develop a set of standardized diagnostic and response criteria for acute myeloid leukemia (AML) clinical trials, and definitions of response for clinical trials are presented to facilitate comparisons among different studies.
Journal ArticleDOI
Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute-sponsored working group
Bruce D. Cheson,John M. Bennett,Kanti R. Rai,Michael R. Grever,Neil E. Kay,Charles A. Schiffer,Martin M. Oken,Michael J. Keating,David H. Boldt,Sanford Kempin,Kenneth A. Foon +10 more
TL;DR: The National Cancer Institute‐sponsored Chronic Lymphocytic Leukemia (CLL) Working Group was convened to develop a set of standardized eligibility, response, and toxicity criteria for clinical trials, and the emergence of several chemotherapy agents that promise impressive activity in CLL is witnessed.
Journal ArticleDOI
Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping.
Gary M. Glazer,Barry H. Gross,Leslie E. Quint,I R Francis,Fred L. Bookstein,Mark B. Orringer +5 more
TL;DR: CT was used to investigate the number and size of normal mediastinal lymph nodes at 11 intrathoracic nodal stations defined by the American Thoracic Society lymph-node mapping scheme, and thresholds were set above which nodes in any region might be considered enlarged.
Related Papers (5)
Revised response criteria for malignant lymphoma
Bruce D. Cheson,Beate Pfistner,Malik E. Juweid,Randy D. Gascoyne,Lena Specht,Sandra J. Horning,Bertrand Coiffier,Richard I. Fisher,Anton Hagenbeek,Emanuele Zucca,Steven T. Rosen,Sigrid Stroobants,T. Andrew Lister,Richard T. Hoppe,Martin Dreyling,Kensei Tobinai,Julie M. Vose,Joseph M. Connors,Massimo Federico,Volker Diehl +19 more
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp,D. P. Harrington,James R. Anderson,James Olen Armitage,Gianni Bonadonna,G. Brittinger,Fernando Cabanillas,George P. Canellos,Bertrand Coiffier,Joseph M. Connors,R. A. Cowan,D. Crowther,Steve Dahlberg,M. Engelhard,Richard I. Fisher,Christian Gisselbrecht,Sandra J. Horning,Eric Lepage,T. A. Lister,J. H. Meerwaldt,Emili Montserrat,Nis I. Nissen,M. M. Oken,Bruce A. Peterson,Carlo Tondini,W. A. Velasquez,B. Y. Yeap +26 more